I
Indalo Therapeutics
A preclinical-stage biotechnology company
About Indalo Therapeutics
Indalo Therapeutics is a biopharmaceutical company focused on developing innovative treatments for serious fibrotic diseases. The company operates in the healthcare and pharmaceutical market, primarily targeting conditions where fibrosis, or the thickening and scarring of connective tissue, is a significant concern. Indalo's lead product, IDL 2965, is an oral drug candidate that uniquely inhibits multiple processes of pathological fibrosis. This includes the local activation of TGF-beta by both epithelial cells and fibroblasts, as well as the ability of a stiff extracellular matrix to promote fibroblast migration and survival. IDL 2965 began human clinical trials in 2019, marking a significant milestone in the company's development pipeline.
Indalo Therapeutics serves patients suffering from chronic fibrotic diseases, with a particular focus on liver fibrosis. The company's business model revolves around the discovery and development of novel integrin antagonists, which are compounds that inhibit integrins, proteins that play a key role in cell signaling and the progression of fibrosis. Revenue is generated through the development and potential commercialization of these therapeutic candidates, as well as through partnerships and collaborations with other pharmaceutical companies.
Source: Dealroom company dataNews
Open roles
Indalo Therapeutics in the St. Louis ecosystem
The Indalo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Indalo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Indalo Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


